What do systematic reviews say?

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 2.5 mg/kg (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 2 [0.2, 20.33]
  1 study · 40 participants
  Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

• Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 127 participants
  Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

• Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 127 participants
  Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

• Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 127 participants
  Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

The review found no eligible studies for this question.

• Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

100 mg olorinab 3 times/day vs 25 mg olorinab 3 times/day

The review found no eligible studies for this question.

• Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

100 mg olorinab 3 times/day vs 25 mg olorinab 3 times/day

The review found no eligible studies for this question.

• Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

100 mg olorinab 3 times/day vs 25 mg olorinab 3 times/day

It is very uncertain whether 100 mg olorinab 3 times/day changes pain intensity (30% reduction in weekly AAPS) compared with 25 mg olorinab 3 times/day (very low certainty).

• Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  RR 0.66 [0.38, 1.15]
  1 study · 14 participants
  Very low

100 mg olorinab 3 times/day vs 25 mg olorinab 3 times/day

• Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 14 participants
  Very low

Budesonide 6‐9 mg vs azathioprine (AZA)

It is very uncertain whether budesonide 6‐9 mg changes continued remission at 12 months compared with azathioprine 2‐2.5 mg/kg (very low certainty).

• Budesonide for maintenance of remission in Crohn's disease 2014 · Cochrane Headline outcomes only
  RR 0.81 [0.61, 1.08]
  1 study · 77 participants
  Very low